ACA
KPTI icon

Acorn Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Acorn Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Buy
1,518,113
+1,230,287
+427% +$10.7M 4.05% 8
2026
Q1 		$1.6M Buy
+287,826
New +$2.19M 0.46% 18

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Acorn Capital Advisors's KPTI Position: Q2 2026 in Review

Acorn Capital Advisors increased its Karyopharm Therapeutics (KPTI) stake by 427% in Q2 2026, buying an estimated $10.7M and bringing the position to 1,518,113 shares worth $14.8M. The position accounts for 4.05% of the portfolio, ranked #8.

Acorn Capital Advisors first reported a position in KPTI in Q1 2026 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Acorn Capital Advisors held 1,518,113 shares of Karyopharm Therapeutics worth $14.8M as of Q2 2026.
  • Acorn Capital Advisors bought 1,230,287 Karyopharm Therapeutics shares in Q2 2026, an estimated $10.7M.
  • Karyopharm Therapeutics made up 4.05% of Acorn Capital Advisors's portfolio in Q2 2026, its #8 holding.
  • Acorn Capital Advisors first reported a position in Karyopharm Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.